Contraceptive Drugs- Market Insights, Competitive Landscape and Market Forecast-2027
Medical Market (7-10 Business Days) I 2022-07-01 I 100 Pages I DelveInsight
Contraceptive Drugs Market By Product Type (Oral Contraceptive Pills [Combination And Progestin-Only], Injectables, Topical Contraceptives [Gels & Jellies, Patches, And Creams]), By Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies, And Others), and by geography is expected to grow at an appreciable CAGR forecast till 2027 owing to rising cases of unitended pregnanices across the globe as well as extensive product development activities in contraceptive drugs
Global contraceptive drugs market was valued at USD 8.59 billion in 2021, growing at a CAGR of 4.32% during the forecast period from 2022 to 2027 to reach USD 11.04 billion by 2027. The contraceptive drugs market is witnessing an explosion in product demand due to numerous reasons such as the increasing number of cases of unintended pregnancies among people. Another contributing factor is the rising focus of national and international organizations on popularizing family planning programs and activities across the globe to possibly reduce population burden in coming years. Additionally, product development activities in terms of non-hormonal products such as the Phexxi gel, product approvals, and regulatory support such as assigning of special designations also play a key role in establishing an upward growth trend in the contraceptive drugs market during the forecast period from 2022 to 2027.
Contraceptive Drugs Market Dynamics:
One of primary factor driving the contraceptives market growth is the upsurge in cases of unintended pregnancies across the globe, which is expected to influence the demand for contraceptive drugs. For instance, as per the data provided by the World Health Organization (2022), 4 million women living in low and middle-income countries have unintended pregnancies annually across the globe. This leads to 25 million unsafe abortions and 47,000 maternal deaths every year globally. Modern methods of contraception have a vital role in preventing unintended pregnancies. The United Nation's Department of Economic and Social Affairs 2019 statistics mentioned that approximately 922 million women of reproductive age (or their partners) use contraception methods comprising various products of which contraceptive pills are one of the most common and reliable sources for avoiding unintended pregnancies. Moreover, as per numbers revealed by the United Nations, in 2021, over 1.4 billion unintended pregnancies happened as an impact of the COVID-19 pandemic which resulted in global disruption of the supply chain of contraceptives including contraceptive drugs. This primarily affected developing nations as majority of the population receive their contraceptive drugs from government-run centers. The impact of the disruption of the supply chain of contraceptive drugs and direct surge in unintended pregnancies across the globe majorly in emerging economies further helped lay emphasis on the growing need for contraceptive drugs across the globe, thereby providing a positive growth outlook for the contraceptive drugs market during the forecast period.
Another prominent factor responsible for the increasing demand of contraceptive drugs is the growing focus of governments as well as international organizations in popularizing population control is expected to drive the demand for contraceptives during the forecast period. For instance, keeping in line with the sustainable development goals for 2030 (SDG 2030) put forth by the United Nations, the Family Planning 2030 program aims at achieving voluntary modern contraceptive use by anyone who wants it by investing in adolescents and youth, strengthening supply chains so that contraceptive drugs reach those who need them, ensuring that family planning services and supplies have sustained funding support, and improving the quality of care in family planning service. The United Nations Population Fund which is a global partnership among alliance of governments, foundations, multilateral agencies, civil society and youth organizations, and private sector partners that are collaborating to advance rights-based family planning have committed a collected fund of USD 3.1 billion toward widening access to family planning over the next five years. Similarly, efforts are also being made by several governments at national level in order to advocate planned parenthood and decrease incidents of maternal mortality. For example, the Indian government initiated a slew of measures to sensitize people and create awareness regarding population control by launching programs such as Mission Parivar Vikas (launched in 2016) which aims to reduce the total fertility rate to 2.1 by the year 2025 in 7 high populated states of the country. Other measures include clinical outreach teams (COT) scheme and compensation scheme for sterilization acceptors among others. Therefore, the growing emphasis on planned parenthood in order to avoid unintended pregnancies and outcomes associated with it such as financial burden, risk to maternal and fetal health are prompting governments and organizations working in the domain to popularize the need for contraception leading to an overall increase in the contraceptive drugs market growth.
However, side-effects associated with contraceptive drugs and no protection against sexually transmitted diseases may prove to be deterrents to contraceptive drugs market growth.
Besides the above-mentioned factors, the contraceptive drugs market was impacted by the imposition of the lockdown due to the COVID-19 pandemic. Even though this specific market maintained a high product demand during the COVID-19 pandemic, there was a significant disruption in supply chain wherein products such as contraceptive pills, creams, and gels failed to reach government-run distribution centers primarily in developing countries. Although, the post-pandemic scenario provides an opportune environment for revenue generation for the contraceptive drugs market due to the resumption of activities in full capacity helping in the restoration of supply chain thereby improving the market outlook for the contraceptive drugs market during the forecast period (2022-2027).
Contraceptive Drugs Market Segment Analysis:
Contraceptive Drugs Market by Product Type (Oral Contraceptive Pills [Combination and Progestin-Only], Injectables, Topical Contraceptives [Gels & Jellies, Patches, and Creams]), by Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of the contraceptive drugs market, oral contraceptive pills is estimated to account for significant revenue share in the year 2021. Between the two, the combined oral contraceptive pills were more popular in 2021. This can be ascribed to the advantages associated with the combined oral contraceptive pills. These pills have proven to be 99% effective when taken correctly following the recommended regimen. Besides helping in providing contraceptive benefits, combined contraceptive pills offer other benefits such as helping with the premenstrual syndrome, heavy periods, acne, among other indications. Considering the advantages associated with the combined oral contraceptive pills, there has been a growing interest in product launches for the same, for instance, in April 2021, Mayne Pharma received the regulatory approval from the US Food and Drug Administration (FDA) for their combined oral contraceptive- NEXTSTELLIS (3 mg drospirenone [DRSP] and 14.2 mg estetrol [E4] tablets). Therefore, the market for combined oral contraceptive pills is predicted to register remarkable growth during the forecast period eventually driving the growth of contraceptive drugs market in coming years.
North America is expected to dominate the overall Contraceptive Drugs Market:
Among all the regions, North America is projected to amass the largest share in revenue generation in the contraceptive drugs market. Some of the factors responsible for the growth of the North America contraceptive drugs market is the rising incidence of unintended pregnancies in the region, rise in focus towards family planning and prevention of unintended pregnancy, growing use of contraceptive drugs amongst females for, and rising awareness pertaining to modern contraception methods.
One of the prominent markets in the North American region is the United States. An increase in unintended pregnancies is one the key factors leading to the growing need for contraceptive drugs, thereby causing an increase in the overall growth of contraceptive drugs market. For instance, as per the Office of Disease Prevention and Health Promotion (2021), in 2020, almost half (45%) of the 6.1 million annual pregnancies in the United States were found to be unintended. In addition, the rising number of medication abortions also present a scenario for the demand for contraceptive drugs. For instance, as per the Guttmacher Institute, in 2020, medical abortions accounted for the largest share in all of US abortions. This could further be attributed to the disruption of the supply chain due to the COVID-19 pandemic which affected the production as well as the distribution of the contraceptive drugs across the country. In addition to the facts stated above, the extensive research and development activities focused on developing male as well as non-hormonal contraceptive drugs is another factor that may contribute in the growth of the United States contraceptive drugs market. For example, one such product in development is the contraceptive gel intended to be used by men which is in clinical trials in the United States, among other countries. The gel formulation was developed by the Population Council and NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The gel contains segesterone acetate, a synthetic progestin, which blocks natural testosterone production in the testes and reduces sperm production. Therefore, such initiatives and product development activities are expected to pave the way for new products to reach the market, thereby providing a prosperous growth environment for the contraceptive drugs market growth in the coming years in the United States as well as in the North America region.
Contraceptive Drugs Market Key Players:
Some of the key market players operating in the contraceptive drugs market includes Abbvie Inc, BAYER AG, Viatris Inc, Gedeon Richter Plc., Agile Therapeutics, Evofem Biosciences, Inc., Amneal Pharmaceuticals LLC., Pfizer Inc, Hana, Maxwellia Ltd., Piramal Enterprises, Mankind Pharma, HLL Lifecare Limited, Theramex, Besins Healthcare, Marlborough Pharmaceuticals, Teva Pharmaceuticals USA, Inc, and others.
Recent Developmental Activities in Contraceptive Drugs Market:
In May 2020, the US Food and Drug Administration approved Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females with reproductive potential.
In January 2020, Bayer and Dare Bioscience entered into an exclusive license agreement for the US commercial rights to investigational hormone-free, monthly contraceptive Ovaprene. As per this agreement, Bayer may commercialize Dare's investigational contraceptive product, Ovaprene in the United States once approved by the FDA.
In December 2020, Gedeon Richter Plc. signed an asset purchase agreement with Janssen Pharmaceutica NV in respect of Janssen's Outside US Evra transdermal contraceptive patch assets. The transaction amounted to approximately around USD 263.5 million.
Key Takeaways from the Contraceptive Drugs Market Report Study
? Market size analysis for current contraceptive drugs market size (2021), and market forecast for 5 years (2022-2027)
? The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the contraceptive drugs market.
? Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
? Key companies dominating the global contraceptive drugs market.
? Various opportunities available for the other competitors in the contraceptive drugs market space.
? What are the top performing segments in 2021? How these segments will perform in 2027.
? Which is the top-performing regions and countries in the current contraceptive drugs market scenario?
? Which are the regions and countries where companies should have concentrated on opportunities for contraceptive drugs market growth in the coming future?
Target Audience who can be benefited from this Contraceptive Drugs Market Report Study
? Contraceptive drugs products providers
? Research organizations and consulting companies
? Contraceptive drugs-related organizations, associations, forums, and other alliances
? Government and corporate offices
? Start-up companies, venture capitalists, and private equity firms
? Distributors and traders dealing in contraceptive drugs
? Various end users who want to know more about the contraceptive drugs market and latest technological developments in the contraceptive drugs market.
Frequently Asked Questions for Contraceptive Drugs Market:
1. What are Contraceptive Drugs?
Contraceptive drugs are medication with the primary action to avoid conception by preventing the fusion of the gametes by employing different techniques such as the inhibition of follicular development, ovulation which is followed majorly in oral contraceptive pills, as well as the making the environment hostile for the sperms to survive as followed by spermicidal products.
2. What is the market for Global Contraceptive Drugs?
Global contraceptive drugs market was valued at USD 8.59 billion in 2021, growing at a CAGR of 4.32% during the forecast period from 2022 to 2027 to reach USD 11.04 billion by 2027.
3. What are the drivers for Global Contraceptive Drugs Market?
The contraceptive drugs market is witnessing an explosion in product demand due to numerous reasons such as the increasing number of cases of unintended pregnancies among people. Another contributing factor is the rising focus of national and international organizations on popularizing family planning programs and activities across the globe to possibly reduce population burden in coming years. Additionally, product development activities in terms of non-hormonal products such as the Phexxi gel, product approvals, regulatory support such as assigning of special designations also play a key role in establishing an upward growth trend in the contraceptive drugs market during the forecast period from 2022-2027.
4. Who are the key players operating in Global Contraceptive Drugs Market?
Some of the key market players operating in the contraceptive drugs market includes Abbvie Inc, BAYER AG, Viatris Inc, Gedeon Richter Plc., Agile Therapeutics, Evofem Biosciences, Inc., Amneal Pharmaceuticals LLC., Pfizer Inc, Hana, Maxwellia Ltd., Piramal Enterprises, Mankind Pharma, HLL Lifecare Limited, Theramex, Besins Healthcare, Marlborough Pharmaceuticals, Teva Pharmaceuticals USA, Inc, and others.
5. Which region has the highest share in Contraceptive Drugs market?
Among all the regions, North America is projected to amass the largest share in revenue generation in the contraceptive drugs market. Some of the factors responsible for the growth of the North America contraceptive drugs market is the rising incidence of unintended pregnancies in the region, rise in focus towards family planning and prevention of unintended pregnancy, and rising awareness pertaining to modern contraception methods.
1.Contraceptive Drugs Market Report Introduction
2.Contraceptive Drugs Market Executive Summary
2.1. Scope of the Study
2.2. Market at Glance
2.3. Competitive Assessment
3. Regulatory and Patent Analysis
3.1. The United States
3.2. Europe
3.3. Japan
3.4. China
4. Contraceptive Drugs Market Key Factors Analysis
4.1. Contraceptive Drugs Market Drivers
4.1.1. Rising Number of Unintended Pregnancies
4.1.2. Technological Advancements in Product Development
4.1.3. Rising Initiatives at Global as well as National Levels to Reduce Incidents of Unintended Pregnancies
4.2. Contraceptive Drugs Market Restraints and Challenges
4.2.1. Complications-associated with Contraceptive Drugs
4.2.2. Limitations in Terms of Offering Protection Against Sexually Transmitted Diseases
4.3. Contraceptive Drugs Market Opportunities
4.3.1. Development of Male-Centric Contraceptive Drugs
5. Contraceptive Drugs Market Porter's Five Forces Analysis
5.1. Bargaining Power of Suppliers
5.2. Bargaining Power of Consumers
5.3. Threat of New Entrants
5.4. Threat of Substitutes
5.5. Competitive Rivalry
6. COVID-19 Impact Analysis on Contraceptive Drugs Market
7. Contraceptive Drugs Market Layout
7.1. By Product Type
7.1.1. Oral Contraceptive Drugs
7.1.2.1. Combination
7.1.2.2. Progestin-Only
7.1.2. Injectables
7.1.3. Topical Contraceptives
7.1.3.1. Gels & Jellies
7.1.3.2. Patches
7.1.3.3. Creams
7.2. By Distribution Channel
7.2.1. Hospitals
7.2.2. Clinics
7.2.3. Retail Pharmacies
7.2.4. Online Pharmacies
7.2.5. Others
7.3. By Geography
7.3.1. North America
7.3.1.1. North America Contraceptive Drugs Market, by Country
7.3.1.1.1. United States
7.3.1.1.2. Canada
7.3.1.1.3. Mexico
7.3.2. Europe
7.3.2.1. Europe Contraceptive Drugs Market, by Country
7.3.2.2.1. France
7.3.2.2.2. Germany
7.3.2.2.3. United Kingdom
7.3.2.2.4. Italy
7.3.2.2.5. Spain
7.3.2.2.6. Russia
7.3.2.2.7. Rest of Europe
7.3.3. Asia-Pacific
7.3.3.1. Asia-Pacific Contraceptive Drugs Market, by Country
7.3.3.3.1. China
7.3.3.3.2. Japan
7.3.3.3.3. India
7.3.3.3.4. Australia
7.3.3.3.5. South Korea
7.3.3.3.6. Rest of Asia Pacific
7.3.4. Rest of the World (RoW)
7.3.4.1. RoW Contraceptive Drugs Market, by Region
7.3.4.4.1. Middle East
7.3.4.4.2. Africa
7.3.4.4.3. South America
8. Contraceptive Drugs Market Global Company Share Analysis - Key 3-5 Companies
9. Contraceptive Drugs Market Company and Product Profiles
9.1. Abbvie Inc
9.1.1. Company Overview
9.1.2. Company Snapshot
9.1.3. Financial Overview
9.1.4. Product Listing
9.1.5. Entropy
9.2. BAYER AG
9.2.1. Company Overview
9.2.2. Company Snapshot
9.2.3. Financial Overview
9.2.4. Product Listing
9.2.5. Entropy
9.3. Viatris Inc
9.3.1. Company Overview
9.3.2. Company Snapshot
9.3.3. Financial Overview
9.3.4. Product Listing
9.3.5. Entropy
9.4. Gedeon Richter Plc
9.4.1. Company Overview
9.4.2. Company Snapshot
9.4.3. Financial Overview
9.4.4. Product Listing
9.4.5. Entropy
9.5. Agile Therapeutics
9.5.1. Company Overview
9.5.2. Company Snapshot
9.5.3. Financial Overview
9.5.4. Product Listing
9.5.5. Entropy
9.6. Evofem Biosciences Inc
9.6.1. Company Overview
9.6.2. Company Snapshot
9.6.3. Financial Overview
9.6.4. Product Listing
9.6.5. Entropy
9.7. Amneal Pharmaceuticals LLC
9.7.1. Company Overview
9.7.2. Company Snapshot
9.7.3. Financial Overview
9.7.4. Product Listing
9.7.5. Entropy
9.8. Pfizer Inc
9.8.1. Company Overview
9.8.2. Company Snapshot
9.8.3. Financial Overview
9.8.4. Product Listing
9.8.5. Entropy
9.9. Hana
9.9.1. Company Overview
9.9.2. Company Snapshot
9.9.3. Financial Overview
9.9.4. Product Listing
9.9.5. Entropy
9.10. Maxwellia Ltd
9.10.1. Company Overview
9.10.2. Company Snapshot
9.10.3. Financial Overview
9.10.4. Product Listing
9.10.5. Entropy
9.11. Piramal Enterprises
9.11.1. Company Overview
9.11.2. Company Snapshot
9.11.3. Financial Overview
9.11.4. Product Listing
9.11.5. Entropy
9.12. Mankind Pharma
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4. Product Listing
9.12.5. Entropy
9.13. HLL Lifecare Limited
9.13.1. Company Overview
9.13.2. Company Snapshot
9.13.3. Financial Overview
9.13.4. Product Listing
9.13.5. Entropy
9.14. Theramex
9.14.1. Company Overview
9.14.2. Company Snapshot
9.14.3. Financial Overview
9.14.4. Product Listing
9.14.5. Entropy
9.15. Besins Healthcare
9.15.1. Company Overview
9.15.2. Company Snapshot
9.15.3. Financial Overview
9.15.4. Product Listing
9.15.5. Entropy
9.16. Marlborough Pharmaceuticals
9.16.1. Company Overview
9.16.2. Company Snapshot
9.16.3. Financial Overview
9.16.4. Product Listing
9.16.5. Entropy
9.17. Teva Pharmaceuticals USA, Inc
9.17.1. Company Overview
9.17.2. Company Snapshot
9.17.3. Financial Overview
9.17.4. Product Listing
9.17.5. Entropy
10. KOL Views
11. Project Approach
12. About DelveInsight
13. Disclaimer & Contact Us
Table 1: Competitive Analysis
Table 2: COVID-19 Impact Analysis
Table 3: Contraceptive Drugs Market in Global (2019-2027)
Table 4: Contraceptive Drugs Market in Global by Product Type (2019-2027)
Table 5: Contraceptive Drugs Market in Global by Distribution Channel (2019-2027)
Table 6: Contraceptive Drugs Market in Global by Geography (2019-2027)
Table 7: Contraceptive Drugs Market in North America (2019-2027)
Table 8: Contraceptive Drugs Market in North America by Country (2019-2027)
Table 9: Contraceptive Drugs Market in the US (2019-2027)
Table 10: Contraceptive Drugs Market in Canada (2019-2027)
Table 11: Contraceptive Drugs Market in Mexico (2019-2027)
Table 12: Contraceptive Drugs Market in Europe (2019-2027)
Table 13: Contraceptive Drugs Market in Europe by Country (2019-2027)
Table 14: Contraceptive Drugs Market in France (2019-2027)
Table 15: Contraceptive Drugs Market in Germany (2019-2027)
Table 16: Contraceptive Drugs Market in the United Kingdom (2019-2027)
Table 17: Contraceptive Drugs Market in Italy (2019-2027)
Table 18: Contraceptive Drugs Market in Spain (2019-2027)
Table 19: Contraceptive Drugs Market in Russia (2019-2027)
Table 20: Contraceptive Drugs Market in Rest of Europe (2019-2027)
Table 21: Contraceptive Drugs Market in APAC (2019-2027)
Table 22: Contraceptive Drugs Market in APAC by Country (2019-2027)
Table 23: Contraceptive Drugs Market in China (2019-2027)
Table 24: Contraceptive Drugs Market in Japan (2019-2027)
Table 25: Contraceptive Drugs Market in India (2019-2027)
Table 26: Contraceptive Drugs Market in Australia (2019-2027)
Table 27: Contraceptive Drugs Market in South Korea (2019-2027)
Table 28: Contraceptive Drugs Market in Rest of APAC (2019-2027)
Table 29: Contraceptive Drugs Market in Rest of World (2019-2027)
Table 30: Contraceptive Drugs Market in RoW by Region (2019-2027)
Table 31: Contraceptive Drugs Market in Middle East (2019-2027)
Table 32: Contraceptive Drugs Market in Africa (2019-2027)
Table 33: Contraceptive Drugs Market in South America (2019-2027)
Figure 1: Competitive Analysis
Figure 2: COVID-19 Impact Analysis
Figure 3: Contraceptive Drugs Market in Global (2019-2027)
Figure 4: Contraceptive Drugs Market in Global by Product Type (2019-2027)
Figure 5: Contraceptive Drugs Market in Global by Distribution Channel (2019-2027)
Figure 6: Contraceptive Drugs Market in Global by Geography (2019-2027)
Figure 7: Contraceptive Drugs Market in North America (2019-2027)
Figure 8: Contraceptive Drugs Market in North America by Country (2019-2027)
Figure 9: Contraceptive Drugs Market in the US (2019-2027)
Figure 10: Contraceptive Drugs Market in Canada (2019-2027)
Figure 11: Contraceptive Drugs Market in Mexico (2019-2027)
Figure 12: Contraceptive Drugs Market in Europe (2019-2027)
Figure 13: Contraceptive Drugs Market in Europe by Country (2019-2027)
Figure 14: Contraceptive Drugs Market in France (2019-2027)
Figure 15: Contraceptive Drugs Market in Germany (2019-2027)
Figure 16: Contraceptive Drugs Market in the United Kingdom (2019-2027)
Figure 17: Contraceptive Drugs Market in Italy (2019-2027)
Figure 18: Contraceptive Drugs Market in Spain (2019-2027)
Figure 19: Contraceptive Drugs Market in Russia (2019-2027)
Figure 20: Contraceptive Drugs Market in Rest of Europe (2019-2027)
Figure 21: Contraceptive Drugs Market in APAC (2019-2027)
Figure 22: Contraceptive Drugs Market in APAC by Country (2019-2027)
Figure 23: Contraceptive Drugs Market in China (2019-2027)
Figure 24: Contraceptive Drugs Market in Japan (2019-2027)
Figure 25: Contraceptive Drugs Market in India (2019-2027)
Figure 26: Contraceptive Drugs Market in Australia (2019-2027)
Figure 27: Contraceptive Drugs Market in South Korea (2019-2027)
Figure 28: Contraceptive Drugs Market in Rest of APAC (2019-2027)
Figure 29: Contraceptive Drugs Market in Rest of World (2019-2027)
Figure 30: Contraceptive Drugs Market in RoW by Region (2019-2027)
Figure 31: Contraceptive Drugs Market in Middle East (2019-2027)
Figure 32: Contraceptive Drugs Market in Africa (2019-2027)
Figure 33: Contraceptive Drugs Market in South America (2019-2027)
Figure 34: Market Drivers
Figure 35: Market Barriers
Figure 36: Marker Opportunities
Figure 37: PORTER'S Five Force Analysis
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.